Carmell (NASDAQ:CTCX – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent ratings and price targets for Carmell and Tandem Diabetes Care, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Carmell | 0 | 0 | 0 | 0 | 0.00 |
| Tandem Diabetes Care | 0 | 8 | 11 | 0 | 2.58 |
Tandem Diabetes Care has a consensus target price of $43.88, suggesting a potential upside of 154.24%. Given Tandem Diabetes Care’s stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Carmell.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carmell | $32,839.00 | 113.25 | -$15.44 million | N/A | N/A |
| Tandem Diabetes Care | $940.20 million | 1.22 | -$222.61 million | ($1.46) | -11.82 |
Carmell has higher earnings, but lower revenue than Tandem Diabetes Care.
Risk & Volatility
Carmell has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.
Insider & Institutional Ownership
24.2% of Carmell shares are owned by institutional investors. 29.0% of Carmell shares are owned by company insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Carmell and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carmell | N/A | -217.50% | -50.22% |
| Tandem Diabetes Care | -14.84% | -44.19% | -11.99% |
Summary
Tandem Diabetes Care beats Carmell on 7 of the 12 factors compared between the two stocks.
About Carmell
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.
